Biopharma Co. Says Investor Suit Tries To Go Around Board
Biopharmaceutical company Ultragenyx Pharmaceutical Inc. told a Delaware vice chancellor on Thursday that a derivative stockholder suit claiming company directors are paid excessive salaries is a procedurally improper go-around filed after...To view the full article, register now.
Already a subscriber? Click here to view full article